In addition, SLAMF7, a robust marker of malignant PCs in MM tumors (38, 39), was highly expressed in immune-high MM tumors, which has been regarded as a target for immunotherapy (Elotuzumab). The gene discussed is SLAMF7; the disease is Miyoshi myopathy.